Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.


Delayed Data
As of Sep 03
 -3.06 / -2.01%
Today’s Change
Today|||52-Week Range
Build a Core Position in Biotech Intrexon at These Lower Prices
Sep 03 / TheStreet.com
A Word of Advice for Amgen: Objects in the Mirror Are Closer Than They Appear
Aug 31 / MotleyFool.com
3 Stocks Pushing The Drugs Industry Lower
Sep 03 / TheStreet.com
Alnylam Presents Positive Data on PCSK9 Synthesis Inhibitor
Aug 31 / Zacks.com
Amgen (AMGN) Stock Falls as Novartis Begins Selling Biosimilar Version of Neupogen
Sep 03 / TheStreet.com
Smith & Wesson powers ahead on strong sales
Aug 28 / FT.com
Novartis launches first biological copycat drug in US
Sep 03 / FT.com
Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
Aug 28 / Zacks.com
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.
Sep 03 / Zacks.com
Frontrunning: August 28
Aug 28 / Investing Channel
The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam
Sep 03 / Zacks.com
Time to Buy Amgen After Newly Approved Drug?
Aug 28 / TheStreet.com
Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Sep 02 / Zacks.com
Aug. 28 Premarket Briefing: 10 Things You Should Know
Aug 28 / TheStreet.com
Regeneron and Sanofi Present Encouraging Praluent Data
Sep 02 / Zacks.com
The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macro...
Aug 27 / Zacks.com
AstraZeneca Strikes Deal with Valeant for Psoriasis Drug
Sep 02 / Zacks.com
You Can't Keep Volatility Down Forever
Aug 26 / TheStreet.com
Amgen Inc.'s FDA Approval Holds Blockbuster Potential
Sep 02 / MotleyFool.com
Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Aug 26 / Zacks.com
Morning Buzz : Ambarella (AMBA), Vera Bradley (VRA), Navistar (NAV), BiondVax (BVXV),...
Sep 02 / Investing Channel
US 'big four' biotechs lead sector tumble into bear market
Aug 24 / FT.com
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target?
Sep 02 / Zacks.com
Why Eli Lilly (LLY) was a Bright Spot in the Market on Thursday
Aug 21 / Zacks.com
Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern
Sep 02 / MotleyFool.com
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Aug 20 / MotleyFool.com
Sept. 2 Premarket Briefing: 10 Things You Should Know
Sep 02 / TheStreet.com
Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Aug 19 / Zacks.com
Rigor Mortis Of The Robo-Machines
Sep 01 / Investing Channel